Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Telmisartan 40 mg + Nebivolol 5 mg Tablet
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹180/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
This combination tablet contains Telmisartan, an angiotensin II receptor blocker (ARB), and Nebivolol, a third-generation beta-1 selective blocker with nitric oxide–mediated vasodilatory properties. Telmisartan works by blocking angiotensin II receptors, thereby relaxing blood vessels, reducing vascular resistance, and lowering blood pressure without affecting heart rate significantly. Nebivolol complements this action by reducing heart rate, decreasing myocardial oxygen demand, and promoting vasodilation through NO release, which enhances endothelial function. Together, they provide synergistic antihypertensive effects, offering both peripheral vasodilation and cardioprotection. This combination is particularly beneficial in patients with uncontrolled hypertension on monotherapy, those at high cardiovascular risk, or patients with coexisting conditions such as heart failure, diabetes, or metabolic syndrome. It provides effective 24-hour blood pressure control with once-daily dosing.
Common side effects include dizziness, headache, fatigue, and mild gastrointestinal disturbances. Nebivolol may cause bradycardia (slow heart rate), while Telmisartan can sometimes cause mild hyperkalemia (elevated potassium levels). Rare but serious adverse effects include severe hypotension, allergic reactions, kidney function impairment, and worsening of heart failure in susceptible individuals. Most side effects are dose-dependent and mild.
Telmisartan 40 mg + Nebivolol 5 mg Tablet is indicated for the management of essential hypertension in adults, particularly in patients who require combination therapy to achieve target blood pressure. It is also useful in patients with concomitant heart failure or left ventricular dysfunction as part of a comprehensive cardiovascular risk reduction plan.
This combination should be taken strictly under medical supervision. It is contraindicated in patients with severe bradycardia, advanced heart block, cardiogenic shock, or severe hepatic impairment. Caution is advised in patients with renal impairment, electrolyte disturbances, or heart failure. It is not recommended during pregnancy and breastfeeding, as ARBs can harm fetal development and beta-blockers can affect neonatal heart rate. Alcohol consumption should be minimized as it can potentiate the blood pressure–lowering effect. Dose should not be stopped abruptly, as sudden discontinuation may cause rebound hypertension or worsening of cardiac symptoms. Regular monitoring of blood pressure, heart rate, kidney function, and electrolytes is recommended during therapy.
Store the tablets in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep the medication in its original blister packaging and out of the reach of children. Do not use after the expiry date mentioned on the pack.
Composition : Aspirin 75mg + Rosuvastatin 20mg + Clopidogrel 150mg Tablet
Composition : Aspirin 75mg + Rosuvastatin 10mg + Clopidogrel 75mg Tablet
Composition : Rosuvastatin 10mg + Clopidogrel 75mg Capsule
Composition : Aspirin 75 mg + Rosuvastatin 20 mg + Clopidogrel 75 mg capsule
Composition : Rosuvastatin 10 mg + Ezetimibe 10 mg tablet
Composition : Rosuvastatin Calcium IP eq. to Rosuvastatin (as pellets) 20 mg. + Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg. Excipients q.s.
Composition : Rosuvastatin (5mg) tablet
Composition : Rosuvastatin 5mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin (20mg) tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Telmisartan 40 mg + Nebivolol 5 mg Tablet is a combination antihypertensive medication used for the management of high blood pressure (hypertension) and associated cardiovascular risks. Telmisartan helps relax blood vessels by blocking angiotensin II receptors, while Nebivolol is a beta-blocker that helps regulate heart rate and blood pressure. This combination is widely prescribed in the cardiac and cardiovascular care segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand from cardiologists, physicians, and general practitioners. With the increasing prevalence of hypertension and cardiovascular disorders, combination therapies like Telmisartan and Nebivolol are frequently prescribed, ensuring regular prescription-driven sales and repeat business opportunities.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the cardiac and cardiovascular segment with monopoly rights, quality-assured manufacturing, attractive promotional support, and reliable product availability to help distributors and franchise partners grow their business.
Wholesalers and distributors benefit from strong prescription demand, long-term therapy usage, growing cardiovascular healthcare needs, and repeat patient consumption, making this product a stable and profitable addition to their pharmaceutical portfolio when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in cardiac and antihypertensive formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, promotional support, and PCD pharma franchise opportunities in the cardiovascular care segment.